Intravesical sequential combination of epirubicin and interferon alpha-2b in patients affected by superficial transitional cell carcinoma of the bladder. Results of a pilot study at Palermo University and proposal of a basic research.
Serretta
V
V
Istituto Policattedra di Materie Urologiche, Facoltà di Medicina e Chirurgia, Università di Palermo, Italy.
Corselli
G
G
Pavone
C
C
Pizzuto Antinoro
S A
SA
Pavone-Macaluso
M
M
D000283:Administration, Intravesical; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D010865:Pilot Projects; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015251:Epirubicin